Within the IFNL4 gene on chromosome 19, the major functional switch for hepatitis C risk is the rs368234815 ΔG frameshift polymorphism¹¹ rs368234815 ΔG frameshift polymorphism
the causal variant that controls whether functional IFN-λ4 protein is produced at all. But not all ΔG carriers face the same risk. A second coding variant in exon 2 — rs117648444, which swaps a proline for a serine at position 70 of the IFN-λ4 protein (p.Pro70Ser) — significantly modulates how active the resulting protein actually is. The Ser70 form (S70) is substantially weaker than the ancestral Pro70 (P70), and ΔG carriers who produce the attenuated S70 protein achieve better hepatitis C clearance outcomes than those producing the fully active P70 form. This creates a functional three-tier hierarchy for IFNL4: TT/TT (no protein) > ΔG-S70 (weak protein) > ΔG-P70 (fully active protein).

The Mechanism

rs117648444 is a missense variant²² missense variant
a coding SNP that changes a single amino acid in the protein sequence. On the IFNL4 minus strand, the coding change is c.208C>T; on the genomic plus strand (as reported in genome files), the alleles are G (reference, Pro70) and A (alternate, Ser70). The substitution of serine for proline at position 70 disrupts the local secondary structure of the IFN-λ4 protein — proline is a rigid, helix-breaking residue, while serine introduces a hydroxyl group and greater flexibility. The result is an IFN-λ4 protein with substantially lower capacity to activate downstream interferon-stimulated genes³³ interferon-stimulated genes
ISGs; hundreds of genes whose protein products directly inhibit viral replication, and reduced antiviral activity against viral challenge models.

Crucially, the A allele (Ser70) is only found on haplotypes that also carry the rs368234815 ΔG allele — it has never been observed on the TT (null) background. This means the rs117648444 variant is uninformative for TT/TT individuals (who produce no IFN-λ4 regardless), and its clinical significance is entirely confined to ΔG carriers. The three haplotypes observed in humans are: (1) IFNL4-TT with rs117648444-G (no protein); (2) IFNL4-ΔG with rs117648444-G (fully active P70 protein); and (3) IFNL4-ΔG with rs117648444-A (attenuated S70 protein).

The Evidence

The variant was characterised in Galmozzi & Aghemo 2014⁴⁴ Galmozzi & Aghemo 2014
"Nonsynonymous variant Pro70Ser (rs117648444) in IFNL4 gene identifies carriers of the rs368234815 ΔG allele with higher HCV RNA decline during the first 4 weeks of pegylated interferon and ribavirin therapy in HCV-1 patients", showing that ΔG carriers with the S70 modifier had significantly greater early viral RNA decline than ΔG-P70 carriers, approaching the response of TT/TT non-producers.

The mechanistic evidence was established by Terczynska-Dyla et al. 2014⁵⁵ Terczynska-Dyla et al. 2014
"Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes" using recombinant protein assays: the S70 protein induced significantly lower intrahepatic ISG expression and had weaker antiviral activity than the P70 protein in direct comparison. The same study confirmed that, in population cohorts, individuals predicted to produce only the S70 form had better spontaneous HCV clearance rates than P70 producers — intermediate between TT/TT (best) and ΔG-P70 (worst).

A 2015 comparative analysis of IFNL4 and IFNL3 functional variants⁶⁶ comparative analysis of IFNL4 and IFNL3 functional variants
Terczynska-Dyla et al., Journal of Hepatology found that rs117648444 adds independent prognostic information beyond rs368234815 alone. In African American participants — where the ΔG allele is common and LD structure differs substantially from Europeans — rs368234815 combined with rs117648444 provided stronger association with HCV outcomes than either variant alone or than the traditional rs12979860 IL28B marker.

The clinical reach extends beyond HCV. In IFN-treated HBeAg-negative chronic hepatitis B patients⁷⁷ IFN-treated HBeAg-negative chronic hepatitis B patients
Galmozzi et al. 2018, Liver International, the combination of rs368234815 and rs117648444 genotypes strongly predicted HBsAg seroclearance at 15 years: the 15-year cumulative probability of HBsAg loss was comparable between S70 carriers and TT/TT individuals (both significantly higher than P70 producers), suggesting the same IFN-λ4 activity gradient that governs HCV outcomes also applies to hepatitis B treatment.

A 2017 study of HCV genotype 3 patients in India⁸⁸ HCV genotype 3 patients in India
Datta et al., PMID 28727946 found that failure to genotype rs117648444 causes confounding in IFNL locus association studies: tag SNPs in linkage disequilibrium with ΔG that happen to be correlated with the S70 modifier will show misleadingly strong or weak associations with treatment response depending on their LD pattern.

Practical Implications

For clinical purposes, rs117648444 is most useful as a refinement tool for ΔG carriers identified by rs368234815 genotyping. A ΔG carrier who also has the S70 modifier (rs117648444-AG or AA) faces a different prognosis than a P70 ΔG carrier (GG at this locus with ΔG at rs368234815): their treatment response profile is closer to that of TT/TT non-producers than to the worst ΔG-P70 subgroup.

For the majority of individuals who are TT/TT at rs368234815, this variant carries no clinical significance: they produce no functional IFN-λ4 regardless of what they carry at rs117648444. For individuals who have not been exposed to hepatitis C and have no ongoing risk, the variant is informationally interesting but does not require clinical action.

Interactions

rs117648444 is functionally downstream of rs368234815. The ΔG allele at rs368234815 is the prerequisite for any effect at rs117648444 — only ΔG/TT or ΔG/ΔG individuals at rs368234815 can benefit from S70 status. Among those ΔG carriers, rs117648444 sub-stratifies by protein activity: the A allele (S70) attenuates IFN-λ4 function and shifts outcomes toward the TT/TT tier. For compound genotype interpretation across both variants, see the interaction analysis in the rs368234815 entry. rs12979860 (the original "IL28B" C/T marker) is a proxy tag for the ΔG/TT distinction and does not capture the P70S modification — making combined genotyping of rs368234815 and rs117648444 the most informative approach.

Apolipoprotein B (apoB) is the indispensable structural protein of atherogenic lipoproteins — LDL, VLDL, and IDL. Every LDL particle contains exactly one molecule of apoB-100, a 4,536-amino-acid protein that serves both as the scaffolding for lipoprotein assembly in the liver and as the docking ligand for LDL receptor recognition. When rs121918389 introduces a premature stop codon at position 1477 (Q1477X), the result is apoB-32 — a truncated protein containing only the first 1,476 amino acids of apoB-100, representing just 32% of the full-length protein. This truncation defines one of the founding mutations of familial hypobetalipoproteinemia (FHBL)¹¹ familial hypobetalipoproteinemia (FHBL)
FHBL is a disorder of very low LDL and apoB levels caused by APOB loss-of-function mutations; OMIM 615558.

The Mechanism

The p.Gln1477Ter stop-gain eliminates the C-terminal two-thirds of apoB-100, including the LDL receptor-binding domain (located between residues ~3000–3500). McCormick et al.²² McCormick et al.
McCormick et al. Apolipoprotein B-32: a new truncated mutant of human apolipoprotein B capable of forming particles in the low density lipoprotein range. Biochim Biophys Acta, 1992 showed that apoB-32 is remarkably unusual among short apoB truncations: it is the shortest known apoB variant capable of forming particles in the LDL density range. However, the majority of apoB-32 partitioned to the HDL and lipoprotein-depleted (d>1.21 g/mL) fractions, with only trace amounts appearing in LDL and none detected in VLDL. This means the liver cannot assemble and secrete apoB-32 as functional VLDL particles, causing hepatic fat accumulation while simultaneously depriving the circulation of its normal complement of LDL cholesterol.

In heterozygotes, one APOB allele produces full-length apoB-100 and the other produces apoB-32. The result is approximately 50% reduction in circulating LDL-C and apoB concentrations compared to unaffected individuals. Because apoB-32 is shorter than apoB-48 (the intestinal isoform that terminates at residue 2152), the intestinal chylomicron pathway is preserved through the wild-type allele — heterozygotes retain fat absorption capacity, which is why severe nutritional deficiency is uncommon in this group.

The Evidence

GeneReviews on APOB-FHBL³³ GeneReviews on APOB-FHBL
Burnett, Hooper, Hegele. APOB-Related Familial Hypobetalipoproteinemia. GeneReviews, 2021 summarizes the clinical spectrum: heterozygotes have plasma LDL-C typically below the 5th percentile for age and sex (~3.0 mmol/L or 115 mg/dL), with LDL-C and apoB concentrations approximately one-third of normal. Heterozygotes are usually asymptomatic, though hepatic steatosis — with a three- to five-fold increase in hepatic fat content versus population norms — is common. About 5–10% of heterozygous carriers develop nonalcoholic steatohepatitis (NASH) that may require medical attention; cirrhosis is rare.

Paradoxically, heterozygous APOB-FHBL confers protection against atherosclerotic cardiovascular disease due to lifelong reductions in LDL cholesterol. This mirrors the cardiovascular protection observed with PCSK9 loss-of-function variants and statin therapy — reinforcing that lower LDL, even when caused by a truncating variant, is cardioprotective.

Tarugi et al. 2001⁴⁴ Tarugi et al. 2001
Tarugi et al. Phenotypic expression of familial hypobetalipoproteinemia in three kindreds with mutations of apolipoprotein B gene. Journal of Lipid Research, 2001 examined apoB truncation length and hepatic outcomes across three kindreds, finding that fatty liver develops invariably in carriers of short and medium truncations (shorter than apoB-48), while longer forms require additional environmental co-factors such as alcohol or metabolic syndrome. The Q1477X mutation producing apoB-32 falls squarely in the "short truncation" category and reliably causes hepatic steatosis.

Practical Actions

For heterozygous carriers (AG genotype), the primary clinical priorities are: (1) confirming the lipid phenotype, (2) monitoring for hepatic steatosis progression, and (3) maintaining fat-soluble vitamin sufficiency. Although heterozygotes rarely develop severe vitamin deficiency, the three- to five-fold increase in hepatic fat indicates that fat absorption and transport are measurably impaired. Monitoring fat-soluble vitamin levels (particularly vitamins E and D) annually is warranted.

Dietary fat intake does not need to be severely restricted in heterozygotes — unlike biallelic FHBL, where a low-fat diet is essential. However, minimizing hepatic fat accumulation by reducing refined carbohydrates and excess dietary fat is reasonable. Alcohol should be minimized, as it is an established hepatic steatosis co-factor.

Interactions

The Q1477X allele interacts in compound heterozygous fashion with other APOB truncating or loss-of-function variants. Compound heterozygosity or homozygosity for APOB truncations produces biallelic FHBL, which resembles abetalipoproteinemia with severe fat malabsorption, fat-soluble vitamin deficiency, and neurological complications if untreated. This is an autosomal recessive severe form requiring aggressive fat-soluble vitamin supplementation and low-fat diet.

The APOB R3527Q variant (rs5742904), which causes familial hypercholesterolemia through defective LDL receptor binding rather than truncation, represents the opposite end of the APOB clinical spectrum — same gene, mechanistically opposite phenotype. Clinicians evaluating unexplained hypocholesterolemia should consider this locus, just as they consider rs5742904 for familial hypercholesterolemia.

Inside the hypothalamus, a cluster of roughly 20,000 neurons called the suprachiasmatic nucleus (SCN)¹¹ suprachiasmatic nucleus (SCN)
The brain's master circadian clock, located in the hypothalamus above the optic chiasm; it generates and coordinates ~24-hour biological rhythms throughout the body fires in near-perfect 24-hour cycles, orchestrating sleep timing, hormone release, and metabolism. Keeping those neurons synchronized — not just cycling individually but entraining as a coherent population — requires molecular conductors. One of the most important is RGS16²² RGS16
Regulator of G-protein Signaling 16; accelerates inactivation of Gαi/o subunits, terminating cAMP signaling pulses and creating a rhythmic window for intercellular synchrony in the SCN.

The variant rs12736689 sits approximately 20 kilobases downstream of the RGS16 gene, in a regulatory region that influences how much RGS16 protein the SCN produces. The C allele — rare at roughly 4% globally — is associated with the strongest morningness signal ever detected in human genetics. Out of hundreds of thousands of genetic variants tested in three independent studies totalling nearly a million people, this single locus has emerged at the top of the chronotype ranking every time.

The Mechanism

RGS16 controls chronotype by gating cAMP³³ cAMP
Cyclic AMP (cyclic adenosine monophosphate), a second messenger that amplifies signals from G-protein-coupled receptors; in the SCN, timed cAMP pulses coordinate neuron-to-neuron communication and synchronize the distributed clock network rhythms within the SCN. RGS16 protein levels themselves cycle over the 24-hour day, creating a timed window during which cAMP can accumulate. This rhythmic cAMP pulse synchronizes the dorsomedial SCN (which drives peripheral body-clock timing) with the ventrolateral SCN (which receives light input from the retina).

Doi et al. (2011)⁴⁴ Doi et al. (2011)
Doi M et al. Circadian regulation of intracellular G-protein signalling mediates intercellular synchrony and rhythmicity in the suprachiasmatic nucleus. Nature Communications, 2011 showed that when RGS16 is deleted in mice, the circadian cAMP rhythm collapses and the behavioral circadian period lengthens. A longer internal period means the clock runs slow relative to the 24-hour day — the animal drifts toward later and later timing, the mouse equivalent of an extreme evening chronotype.

The rs12736689 C allele is in strong linkage disequilibrium⁵⁵ linkage disequilibrium
LD (r²=0.89): the two variants are inherited together so frequently that knowing one allele predicts the other with ~89% accuracy (r²=0.89) with rs1144566, a missense variant (H137R) in the RGS16 coding sequence. The combined evidence suggests that the regulatory and structural variants at this locus jointly modulate RGS16 activity in the SCN, with higher activity corresponding to tighter cAMP gating and a faster, morning-biased clock.

The Evidence

The RGS16 locus is the most robustly replicated single locus in human chronotype genetics, having emerged independently in three large-scale GWAS using different populations and study designs.

Hu et al. (2016)⁶⁶ Hu et al. (2016)
Hu Y et al. GWAS of 89,283 individuals identifies genetic variants associated with self-reporting of being a morning person. Nature Communications, 2016 identified rs12736689 as the top hit in 89,283 23andMe participants, with the T allele (non-morningness) showing OR 0.74 (95% CI 0.69–0.79) at P=7.0×10⁻¹⁸ — meaning the C allele confers approximately 1.35-fold higher odds of being a morning person per allele. Seven of the 15 significant loci clustered near established circadian genes, and RGS16 stood apart as the most significant of all.

Jones et al. (2016)⁷⁷ Jones et al. (2016)
Jones SE et al. Genome-Wide Association Analyses in 128,266 Individuals Identifies New Morningness and Sleep Duration Loci. PLoS Genetics, 2016 independently identified the same RGS16 locus (lead SNP rs516134, in high LD with rs12736689) as the top chronotype hit in the UK Biobank, with OR 1.21 for the morningness allele at P=3×10⁻¹².

The definitive meta-analytic confirmation came from Jones et al. (2019)⁸⁸ Jones et al. (2019)
Jones SE et al. Genome-wide association analyses of chronotype in 697,828 individuals provides insights into circadian rhythms. Nature Communications, 2019, expanding the chronotype locus catalog to 351 genome-wide significant loci in 697,828 participants. The RGS16 locus remained the top hit. Mendelian randomization in this study established that the genetic component of morningness causally associates with better mental health outcomes — likely because earlier chronotype aligns more closely with typical daylight-hour social and work schedules.

Practical Implications

For TT homozygotes (the large majority), circadian timing sits at the population average — slightly toward the evening end of the spectrum relative to C allele carriers, but solidly typical. Environmental factors (morning light, meal timing, consistent schedule) are the primary levers for shaping rhythm.

For carriers of one or two C alleles, the RGS16 mechanism shifts the clock toward earlier timing. The practical benefit — alignment with conventional work schedules and better morning alertness — is real but modest at this single locus. The main risk is the rigid early clock: evening social or professional demands can conflict acutely with a biologically advanced sleep phase, and C allele carriers typically find it harder to stay up late without next-day consequences.

Interactions

rs12736689 and rs516134 both tag the same RGS16 regulatory region (r² ~0.89 with rs1144566). Carriers with other morningness variants — in CLOCK (rs1801260), PER3 (rs5751876), PER2 (rs55694368), or the VIP signaling gene (rs9479402) — may experience additive phase advances. Evening-allele carriers at multiple circadian loci show the greatest benefit from structured morning-light and meal-timing interventions to advance their clock.

Dystrophin¹¹ Dystrophin
A 427 kDa cytoskeletal protein encoded by one of the largest genes in the human genome, spanning 2.4 Mb on the X chromosome. It forms a critical mechanical link between the intracellular actin cytoskeleton and the extracellular matrix in both skeletal and cardiac muscle. is the protein that keeps muscle fibres from tearing apart during every contraction. When full-length dystrophin is lost, the sarcolemma becomes fragile, membrane micro-ruptures accumulate with each heartbeat, and cardiomyocytes die faster than they can be replaced — culminating in dilated cardiomyopathy (DCM)²² dilated cardiomyopathy (DCM)
A form of heart failure in which the ventricles enlarge and weaken, reducing the heart's pumping capacity. In DMD-associated DCM, this is the direct result of dystrophin-deficient cardiomyocyte death..

The rs128627256 variant — NM_004006.3:c.8713C>T (p.Arg2905Ter) in the full-length muscle isoform Dp427m — converts an arginine codon to a premature stop codon in the last exon region of the dystrophin rod domain. It is classified as pathogenic in ClinVar (Variation 11288) and is associated with Duchenne muscular dystrophy, Becker muscular dystrophy, and dilated cardiomyopathy 3B (OMIM 302045) depending on the degree of residual protein produced and the specific isoforms affected.

The Mechanism

Full-length dystrophin (Dp427) is expressed in both skeletal and cardiac muscle. Shorter isoforms (Dp260, Dp140, Dp71) are expressed in the retina, brain, and other tissues. The p.Arg2905Ter nonsense mutation introduces a premature stop codon that triggers nonsense-mediated mRNA decay³³ nonsense-mediated mRNA decay
A cellular quality-control pathway that degrades mRNAs containing premature stop codons, preventing production of truncated proteins that could be toxic. for the full-length isoforms, eliminating or severely reducing full-length dystrophin protein. Without dystrophin, the dystrophin-associated protein complex (DAPC) at the sarcolemma disassembles, leaving the muscle cell membrane unanchored and vulnerable to contraction-induced damage.

In the heart, this loss is insidious: cardiac cells do not regenerate the way skeletal muscle does, so each injury event is permanent. Over years to decades, cumulative cardiomyocyte loss leads to ventricular dilation, fibrosis, and progressive systolic dysfunction. Cardiomyopathy occurs in nearly all males with DMD after age 18, and heart failure from DCM is the most common cause of death in Becker muscular dystrophy⁴⁴ heart failure from DCM is the most common cause of death in Becker muscular dystrophy
In BMD, skeletal muscle involvement is milder and patients survive longer, making the cardiac phenotype the dominant clinical problem. Mean age of death from cardiac causes is in the mid-40s..

The Evidence

GeneReviews Dystrophinopathies⁵⁵ GeneReviews Dystrophinopathies
Darras et al., updated 2022 — PMID 20301298 synthesises decades of natural history data: cardiomyopathy affects approximately one-third of DMD males by age 14, one-half by age 18, and virtually all by adulthood. Complete cardiac evaluation is recommended at least every two years from diagnosis, with annual evaluations from approximately age 10.

For female carriers, the picture is more nuanced. A systematic review by Ishizaki et al. (2018) — PMID 29801751⁶⁶ Ishizaki et al. (2018) — PMID 29801751 found dilated cardiomyopathy in 7.3–16.7% of female DMD carriers, with frequency increasing with age. A focused review by Lim et al. (2020) — PMID 32650403⁷⁷ Lim et al. (2020) — PMID 32650403 placed the overall DCM rate at ~8% of female carriers, while noting heterogeneity driven by X-inactivation patterns: females with skewed X-inactivation (where the variant-bearing X is preferentially active) face substantially higher cardiac risk than those with balanced inactivation.

An analysis of adult-onset DCM cohorts by Johnson et al. (2023) — PMID 37671549⁸⁸ Johnson et al. (2023) — PMID 37671549 found pathogenic DMD variants in 12.5% of unselected male DCM probands, with high rates of heart failure, transplantation, and ventricular arrhythmias — underscoring that DMD-associated DCM is not rare in adult cardiology practice, even when the neuromuscular diagnosis was never made.

Practical Actions

The cardiac risk from DMD variants is manageable with systematic early surveillance. In males with a confirmed DMD pathogenic variant, Bourke et al. (2022) — PMID 36252992⁹⁹ Bourke et al. (2022) — PMID 36252992 recommend cardiac MRI in addition to echocardiography, with ACE inhibitors or angiotensin receptor blockers initiated when left ventricular ejection fraction (LVEF) falls below 55% (or sometimes prophylactically), and beta-blockers added when LVEF falls below 45%. Heart transplant and mechanical circulatory support are options for end-stage disease.

For female carriers, GeneReviews recommends¹⁰¹⁰ GeneReviews recommends a complete cardiac evaluation by a specialist in late adolescence or early adulthood, then every five years from age 25–30. Any new cardiorespiratory symptoms warrant earlier evaluation. Pregnancy increases cardiac demands and is a recognized trigger for decompensation in carrier females — obstetric teams should be aware of carrier status.

Genetic counseling is essential for the extended family. In X-linked inheritance, an affected male passes the variant to all daughters (who become obligate carriers) and no sons. A carrier female has a 50% chance of passing the variant to each son (who would be affected) and each daughter (who would become a carrier).

Interactions

No inter-SNP compound action is warranted for this variant. Cardiac risk in males depends primarily on the presence of any pathogenic DMD variant that abolishes full-length dystrophin, rather than on interactions with other common SNPs. In females, cardiac risk is modulated by X-inactivation status¹¹¹¹ X-inactivation status
The process by which one X chromosome is silenced in each cell of a female. If the variant-bearing X is disproportionately active (skewed X-inactivation), more cells produce defective dystrophin and cardiac risk rises substantially. but this is not captured by a second SNP — it requires X-inactivation assays. DMD gene variants that truncate different isoforms may show variable skeletal muscle severity, but cardiac involvement is broadly present across truncating variants.

In 2008, Bradley Willcox and colleagues published what became the most influential longevity genetics paper of the decade. Scanning insulin/IGF-1 pathway genes in 3,741 Japanese American men enrolled in the Honolulu Heart Program, they identified three variants in FOXO3A simultaneously associated with extreme longevity: rs2764264, rs2802292, and rs13217795. The OR for homozygous minor vs. major alleles was 2.75¹¹ The OR for homozygous minor vs. major alleles was 2.75
Willcox BJ et al. FOXO3A genotype is strongly associated with human longevity. Proc Natl Acad Sci USA. 2008, and men with the longevity genotype showed healthier cardiovascular profiles, lower cancer rates, and better metabolic function.

Of the three discovery variants, rs13217795 has received the least independent mechanistic attention — until recently. Frankum et al. 2022²² Frankum et al. 2022
Extreme longevity variants at the FOXO3 locus may moderate FOXO3 isoform levels. Geroscience. 2022 demonstrated that the C allele at rs13217795 is specifically associated with a shift in FOXO3 isoform balance: more full-length FOXO3 protein, and fewer truncated isoforms that lack a complete forkhead DNA-binding domain. This provides a molecular explanation for how this regulatory variant, sitting in FOXO3's intron, could influence longevity — not by changing how much FOXO3 is made, but by changing what kind is made.

The Mechanism

rs13217795 sits in intron 2 of FOXO3 (intron 5 in some transcript annotations) at chromosome 6 position 108,652,895 on GRCh38. It is part of the same haplotype block as rs2802292 and rs2764264 — the three variants travel together in populations but are not in complete linkage disequilibrium, each capturing some independent information.

The mechanistic focus for this specific variant centers on the FOXO3-TR isoform: a 5' truncated form of FOXO3 that lacks the amino-terminal transactivation domain and part of the forkhead DNA-binding domain. FOXO3-TR can be expressed from an alternative promoter embedded within intron 2 — and rs13217795 maps to the regulatory region controlling this alternative transcription start site.

Frankum et al. found that in skeletal muscle tissue (where FOXO3-TR is expressed at detectable levels, unlike blood), carriers of the C allele showed significantly reduced FOXO3-TR isoform levels compared to TT homozygotes. Because FOXO3-TR lacks a complete forkhead domain, it cannot bind target DNA and activate the downstream programs that underlie FOXO3's protective functions — antioxidant gene induction, autophagy, DNA repair, and attenuation of NF-κB inflammatory signaling. The shift away from FOXO3-TR toward full-length functional FOXO3 in C-allele carriers therefore tilts the cellular balance toward effective stress resistance.

This mechanism is distinct from the other FOXO3 longevity variants: rs2802292 creates an HSF1 binding site that amplifies FOXO3 transcription under stress, while rs2764264 disrupts an NKX3 repressor binding site. rs13217795 operates through a third axis — isoform composition rather than transcription level — providing partially independent contribution to the overall FOXO3 longevity architecture.

The Evidence

The association evidence for rs13217795 is well-replicated. A meta-analysis of 11 independent studies³³ A meta-analysis of 11 independent studies
Bao JM et al. Association between FOXO3A gene polymorphisms and human longevity: a meta-analysis. Asian J Androl. 2014 covering 5,241 long-lived cases and 5,724 controls found the minor allele associated with OR = 1.27 (95% CI 1.10–1.46, p = 0.001). Unlike rs2764264 (which shows male-specific effects) and rs2802292 (which shows the strongest effect in males but replicates in mixed-sex cohorts), rs13217795 shows associations across both sexes in the meta-analysis.

Soerensen et al. 2010⁴⁴ Soerensen et al. 2010
Replication of an association of variation in the FOXO3A gene with human longevity using both case-control and longitudinal data. Aging Cell. 2010 confirmed rs13217795 in Danish oldest-old (the 1905 birth cohort, n=1,089) vs. middle-aged controls (n=736), with the variant remaining significant after multiple-testing correction in males under a recessive model (corrected p = 0.025).

Replication has spanned Chinese nonagenarians and centenarians He et al. 2014⁵⁵ He et al. 2014
FOXO3 variant confirmed in 567 Chinese long-lived individuals vs 508 controls; p=0.0075 codominant model. Aging (Albany NY). 2014, and Northern Indian elderly Hussain et al. 2022⁶⁶ Hussain et al. 2022
C allele associated with lower fasting glucose, insulin, HOMA-IR, CRP, TNF-α, and IL-6 in elderly North Indian patients. Mol Syndromol. 2022, confirming that the longevity signal at rs13217795 extends beyond the original Japanese American discovery population.

The metabolic dimension is particularly actionable. In the Hussain 2022 study, CC homozygotes with diabetes showed significantly lower fasting plasma glucose (FPG), insulin resistance (HOMA-IR), and inflammatory markers (TNF-α, CRP) compared to TT homozygotes — suggesting the C allele's protective isoform shift translates into measurable metabolic advantages relevant to the diabetes-longevity connection.

Practical Actions

The isoform mechanism of rs13217795 has a clear lifestyle correlate. FOXO3-TR expression is regulated by nutrient signaling: high insulin/IGF-1 states (caloric excess, metabolic syndrome, chronic hyperinsulinemia) tend to suppress full-length FOXO3 in favor of alternative promoter usage. C allele carriers already have a genetic bias toward less FOXO3-TR — but TT homozygotes can partially compensate through lifestyle choices that lower circulating insulin and IGF-1.

Specifically, time-restricted eating, intermittent fasting, and low-glycemic dietary patterns reduce insulin/IGF-1 signaling — the same pathway that determines the ratio of full-length to truncated FOXO3. Exercise (particularly resistance training and HIIT) activates FOXO3 through AMPK and SIRT1 pathways, providing an alternative route to FOXO3 activation that bypasses the need for the isoform regulatory advantage conferred by the C allele.

For those with the TT genotype, the metabolic associations from the Hussain 2022 data (higher glucose, higher HOMA-IR, elevated TNF-α and IL-6) suggest particular vigilance around insulin sensitivity and inflammatory markers.

Interactions

rs13217795 belongs to the primary FOXO3 longevity haplotype block together with rs2802292 and rs2764264. These three variants were discovered together in the original 2008 Willcox study and remain in partial linkage disequilibrium, particularly in Asian populations. However, they operate through distinct molecular mechanisms, meaning the effects are partially additive rather than entirely redundant.

The three-mechanism model for FOXO3 longevity: - rs2802292 (G allele): creates an HSF1 binding site → more FOXO3 transcription under stress - rs2764264 (C allele): removes an NKX3 repressor binding site → higher basal FOXO3 expression - rs13217795 (C allele): reduces FOXO3-TR truncated isoform → more functional FOXO3 protein per transcript

rs12206094 and rs4946935 (identified by Flachsbart et al. 2017) provide additional independent longevity signals through CTCF and SRF binding mechanisms, completing a picture of at least five functionally distinct regulatory elements contributing to FOXO3 expression and function across the human lifespan.

Your cells have a sophisticated waste disposal and defense system called autophagy — literally "self-eating" — that wraps up cellular debris, damaged organelles, and invading bacteria in membranous sacks and destroys them. IRGM (Immunity-Related GTPase M) acts as a master regulator of this process, especially in the gut, where it coordinates your intestinal cells' response to the trillions of bacteria living in your digestive tract.

The rs13361189 variant sits in a regulatory region 4,299 base pairs upstream of the IRGM gene¹¹ 4,299 base pairs upstream of the IRGM gene
This promoter position affects gene transcription, and it's in perfect linkage disequilibrium²² perfect linkage disequilibrium
Two variants are always inherited together with a 20-kilobase deletion that fundamentally alters how much IRGM your cells produce. This isn't just an academic curiosity — it's one of the strongest genetic risk factors for Crohn's disease, a chronic inflammatory bowel condition that affects millions worldwide.

The Mechanism

IRGM is a GTP-binding protein that functions as a platform for assembling the core autophagy machinery. When a bacterial cell enters your intestinal epithelium — either a pathogen breaching the barrier or a commensal bacterium that's wandered where it shouldn't — IRGM springs into action. It physically interacts with NOD2 and ATG16L1³³ physically interacts with NOD2 and ATG16L1
Two other major Crohn's disease risk genes, creating a molecular complex, recruiting the autophagy initiation proteins ULK1 and BECN1 to the invasion site.

IRGM also regulates mitochondrial dynamics⁴⁴ regulates mitochondrial dynamics
It controls mitochondrial fission, which is necessary for autophagy, demonstrating differential affinity for the mitochondrial lipid cardiolipin and affecting mitochondrial fission — a process that turns out to be essential for autophagic control of intracellular bacteria like Mycobacterium tuberculosis.

The rs13361189 C allele (the risk variant) reduces IRGM expression by approximately 30-50%⁵⁵ reduces IRGM expression by approximately 30-50%
Measured in whole blood and terminal ileum tissue in carriers. This reduction compromises the cell's ability to quickly wrap invading bacteria in autophagosomes, allowing bacterial persistence and triggering chronic inflammation as the immune system struggles to clear an infection it can't eliminate.

Intriguingly, the same variant also upregulates ZNF300P1⁶⁶ upregulates ZNF300P1
A long non-coding RNA adjacent to IRGM on chromosome 5, a long non-coding RNA that appears to further dysregulate the autophagy pathway, creating a cascade of altered gene expression affecting inflammation and immune response.

The Evidence

The association between IRGM variants and Crohn's disease emerged from genome-wide association studies⁷⁷ genome-wide association studies
GWAS scan millions of genetic variants across thousands of people that identified rs13361189 as one of the strongest signals outside the MHC region, with a combined p-value of 2.1 × 10⁻¹⁰ — extraordinarily robust by genomic standards.

A meta-analysis of seven case-control studies⁸⁸ meta-analysis of seven case-control studies
Including 3,093 Crohn's patients and 3,227 controls confirmed that the C allele increases Crohn's disease risk with a relative risk of 1.25 (95% CI: 1.04-1.50, P=0.016). In the dominant model (CT + CC versus TT), the relative risk is 1.21 (95% CI: 1.03-1.42, P=0.018). While these effect sizes might seem modest, they're clinically meaningful for a complex polygenic disease.

The population genetics tell a fascinating story: the C (risk) allele frequency is approximately 8% in Europeans but jumps to 44% in Africans and 43% in East Asians. Yet Crohn's disease remains primarily a disease of European ancestry populations, suggesting gene-environment or gene-gene interactions⁹⁹ gene-environment or gene-gene interactions
The variant alone isn't sufficient — other factors must be present are required for disease manifestation.

Functional studies have demonstrated that IRGM-deficient cells show impaired autophagy¹⁰¹⁰ IRGM-deficient cells show impaired autophagy
Measured by accumulation of LC3-II and p62, autophagy markers and extended survival of intracellular bacteria including Mycobacterium tuberculosis, Salmonella, and adherent-invasive E. coli (AIEC) — a strain commonly found in Crohn's disease patients.

Perhaps most compelling, rs13361189 minor allele carriers show altered expression¹¹¹¹ rs13361189 minor allele carriers show altered expression
Of dozens of inflammation and autophagy genes beyond just IRGM of multiple genes regulating inflammation and autophagy in both blood and intestinal tissue, including reduced expression of genes involved in bacterial sensing (TLRs) and inflammatory regulation (cytokines), creating a systemic defect in immune homeostasis.

Practical Actions

If you carry one or two C alleles at rs13361189, your autophagy system is working at reduced capacity, particularly in your gut. This has implications beyond Crohn's disease risk — it affects how your body handles gut bacteria, clears cellular debris, and maintains the intestinal barrier.

Autophagy enhancement becomes a priority. Vitamin D is a potent autophagy inducer¹²¹² Vitamin D is a potent autophagy inducer
Through the VDR receptor, it upregulates autophagy genes and specifically promotes intestinal autophagy while modulating gut microbiota. Maintaining adequate vitamin D levels (25-hydroxyvitamin D above 30 ng/mL, ideally 40-60 ng/mL) is particularly important for IRGM variant carriers.

Dietary strategies can support autophagy and reduce inflammatory triggers. A recent randomized controlled trial of fasting-mimicking diet¹³¹³ randomized controlled trial of fasting-mimicking diet
Five consecutive days per month of 700-1,100 calories in Crohn's patients showed that about two-thirds experienced improvement in symptoms, likely through autophagy induction and reduced inflammatory signaling. Even without formal fasting protocols, reducing ultra-processed foods, limiting red and processed meat, and emphasizing fiber from diverse plant sources can help maintain gut microbiome balance.

Butyrate-producing bacteria deserve special attention. People with IRGM variants show reduced abundance of Roseburia and Faecalibacterium¹⁴¹⁴ reduced abundance of Roseburia and Faecalibacterium
Key butyrate producers that support colonocyte health, bacteria that produce the short-chain fatty acid butyrate. Butyrate not only nourishes colonocytes but also induces autophagy through AMPK activation¹⁵¹⁵ induces autophagy through AMPK activation
AMPK inhibits mTOR, the master autophagy suppressor, partially compensating for reduced IRGM function. Resistant starch (found in cooked and cooled potatoes, rice, and legumes), inulin (from Jerusalem artichokes, chicory, garlic), and other fermentable fibers feed these beneficial bacteria.

Monitoring is important for C allele carriers, especially if you have digestive symptoms. Fecal calprotectin¹⁶¹⁶ Fecal calprotectin
A protein released by inflamed intestinal cells, measured in stool is a non-invasive marker of intestinal inflammation that's more specific than blood tests like CRP or ESR. If you have chronic digestive issues — particularly abdominal pain, diarrhea, or unexplained weight loss — request fecal calprotectin testing. Elevated levels (>150 μg/g) warrant gastroenterology referral and possible colonoscopy.

Omega-3 fatty acids (EPA and DHA) support both autophagy and anti-inflammatory signaling. While the evidence is mixed for omega-3s in established Crohn's disease, they may help maintain gut barrier function and reduce low-grade inflammation in at-risk individuals.

Interactions

IRGM doesn't work in isolation — it's part of an interconnected autophagy network¹⁷¹⁷ interconnected autophagy network
Including NOD2 (rs2066844, rs2066845, rs2066847) and ATG16L1 (rs2241880) that includes NOD2 and ATG16L1, two other major Crohn's disease susceptibility genes. NOD2 recognizes bacterial cell wall fragments (muramyl-dipeptide) and recruits ATG16L1 to the bacterial entry site at the plasma membrane, initiating autophagosome formation. IRGM promotes ubiquitination of the complex and assembly of the core autophagy machinery.

When you carry risk variants in multiple autophagy genes — such as IRGM rs13361189 plus NOD2 frameshift mutations (rs2066847) or ATG16L1 T300A (rs2241880) — the combined effect on Crohn's risk is multiplicative¹⁸¹⁸ combined effect on Crohn's risk is multiplicative
Each additional risk allele substantially increases disease susceptibility, not merely additive. A genetic interaction has been documented between rs13361189 and ATG16L1 rs2241880, with compound carriers showing markedly reduced bacterial clearance in functional studies.

The IRGM variant also affects response to certain treatments. While the data is limited, some studies suggest that ATG16L1 variants predict response to anti-TNF biologics¹⁹¹⁹ ATG16L1 variants predict response to anti-TNF biologics
IRGM variants may show similar patterns like adalimumab in Crohn's disease patients, though similar associations for IRGM variants specifically have not been as well characterized.

Beyond Crohn's disease, IRGM variants modify tuberculosis susceptibility²⁰²⁰ modify tuberculosis susceptibility
The same autophagy defect impairs clearance of Mycobacterium tuberculosis, with some studies showing protective effects against active TB progression in rs13361189 C carriers (OR 0.72, 95% CI 0.51-1.01 in Chinese populations), possibly due to altered cytokine responses. The variant also associates with altered risk for other infections where autophagy plays a role in pathogen control.

Inside every cell, the peroxisome acts as a specialized metabolic furnace — the only compartment capable of breaking down very-long-chain fatty acids (VLCFAs)¹¹ very-long-chain fatty acids (VLCFAs)
Fatty acids with 22 or more carbon atoms, such as C24:0 (lignoceric acid) and C26:0 (hexacosanoic acid). These cannot enter the mitochondria for standard beta-oxidation and must first be chain-shortened in peroxisomes before mitochondria can complete the process. and branched-chain fatty acids such as pristanic acid. The HSD17B4 gene encodes D-bifunctional protein (DBP)²² D-bifunctional protein (DBP)
Also called MFP-2 (multifunctional protein 2) or MFPE (multifunctional enzyme 2). DBP is one of two peroxisomal multifunctional enzymes; the other is L-bifunctional protein (ЕХНY1). DBP acts on D-configured intermediates and is responsible for the majority of peroxisomal fatty acid beta-oxidation in humans., a peroxisomal enzyme that catalyzes two consecutive steps of fatty acid chain-shortening: 2-enoyl-CoA hydratase activity (hydration) and 3-hydroxyacyl-CoA dehydrogenase activity (oxidation). Without functional DBP, VLCFAs and branched-chain fatty acids accumulate in tissues, particularly in myelin sheaths and adrenal cortex, causing progressive neurological damage.

The rs137853096 variant substitutes a serine for the glycine at position 16 of the DBP protein (p.Gly16Ser, c.46G>A). Glycine-16 sits within the N-terminal dehydrogenase domain of DBP and is conserved across vertebrates, indicating functional importance. Demain et al. 2017³³ Demain et al. 2017
Demain LA et al. Expanding the genotypic spectrum of Perrault syndrome. Clin Genet, 2017 identified p.Gly16Ser as a recurrent pathogenic allele in Perrault syndrome, found compound heterozygous with a novel p.Val82Phe variant in an affected female with sensorineural hearing loss and primary ovarian insufficiency.

The Mechanism

DBP's dehydrogenase domain requires a precise three-dimensional fold to position the NAD+ cofactor and substrate correctly. Glycine is the smallest amino acid with no side chain, and its presence at position 16 is critical for the tight turn geometry of the N-terminal domain. Substituting serine introduces a hydroxyl side chain that is likely to disrupt local secondary structure and destabilize the dehydrogenase fold, reducing or abolishing enzymatic activity.

When both copies of HSD17B4 carry pathogenic variants, the peroxisomal beta-oxidation pathway is blocked. Two distinct clinical presentations emerge depending on the residual enzyme activity:

Severe neonatal DBP deficiency (classical form): Near-complete loss of activity causes accumulation of VLCFAs, pristanic acid, and bile acid intermediates within days of birth. Infants present with hypotonia, neonatal seizures, polymicrogyria, and facial dysmorphism. Biochemically, elevated C26:0, C26:0/C22:0 ratio, and abnormal bile acids confirm the diagnosis. Chen et al. 2021⁴⁴ Chen et al. 2021
Chen S et al. Two Novel HSD17B4 Heterozygous Mutations in Association With D-Bifunctional Protein Deficiency. Front Pediatr, 2021 reported a neonatal case with significant VLCFA elevation and a fatal outcome at 5 months despite supportive care.

Perrault syndrome (attenuated form): Partial residual DBP activity — as expected with a missense variant like p.Gly16Ser — produces a less severe but still significant phenotype that may not manifest until childhood or adolescence. The cardinal features are sensorineural hearing loss (present in both sexes) and primary ovarian insufficiency (POI) in 46,XX females. Some individuals also develop cerebellar ataxia, peripheral neuropathy, or cognitive difficulties. Pierce et al. 2010⁵⁵ Pierce et al. 2010
Pierce SB et al. Mutations in the DBP-deficiency protein HSD17B4 cause ovarian dysgenesis, hearing loss, and ataxia of Perrault Syndrome. Am J Hum Genet, 2010 established HSD17B4 as a causative gene for Perrault syndrome in compound heterozygous sisters who presented with ovarian dysgenesis, sensorineural hearing loss, and progressive ataxia.

A 2025 study further demonstrated that HSD17B4 deficiency disrupts primary ciliogenesis — Bae et al. 2025⁶⁶ Bae et al. 2025
Bae JE et al. HSD17B4 deficiency causes dysregulation of primary cilia and is alleviated by acetyl-CoA. Nat Commun, 2025 showed that cells carrying the G16S patient variant had reduced cilium formation and length, and that acetyl-CoA supplementation (via acetate) rescued cilia function in patient-derived cells and in Hsd17b4-knockout mice.

The Evidence

DBP deficiency is classified as pathogenic by ClinVar with 17 pathogenic and 3 likely pathogenic submissions across 28 laboratories (VCV000007655, aggregate review: criteria provided, multiple submitters). The variant is associated with two phenotype entries: bifunctional peroxisomal enzyme deficiency (OMIM #261515) and Perrault syndrome 1 (OMIM

233400).

The A allele is extremely rare globally. In gnomAD exomes (v4) it is detected at a frequency of approximately 0.035% (490 out of 1,401,272 alleles) — consistent with a pathogenic variant maintained at low frequency by heterozygous carrier transmission. Crucially, no homozygous individuals have been identified in population databases, consistent with the severe phenotype of biallelic loss of function.

Lieber et al. 2014⁷⁷ Lieber et al. 2014
Lieber DS et al. Next generation sequencing with copy number variant detection expands the phenotypic spectrum of HSD17B4-deficiency. BMC Med Genet, 2014 documented an adult male with compound heterozygous HSD17B4 mutations (a missense plus a 12 kb exonic deletion) who presented with cerebellar ataxia, peripheral neuropathy, hearing loss, and infertility — expanding recognized presentations beyond neonatal disease.

Practical Actions

Because this is an autosomal recessive condition, one copy of p.Gly16Ser (heterozygous carrier) does not produce disease. The single functional HSD17B4 allele produces sufficient DBP activity for normal peroxisomal fatty acid metabolism. The clinical significance of carrier status is exclusively reproductive.

For individuals with biallelic HSD17B4 pathogenic variants, management is supportive: monitoring and management of hearing loss (hearing aids, cochlear implant evaluation), hormonal management of primary ovarian insufficiency in females (typically estrogen replacement therapy), fat-soluble vitamin supplementation (vitamins A, D, E, K) to compensate for potential impaired absorption secondary to peroxisomal dysfunction, and neurological monitoring for emerging ataxia or neuropathy. No enzyme replacement or gene therapy is currently approved; ataluren-mediated readthrough has been explored for nonsense variants.

Interactions

HSD17B4 encodes a bifunctional protein with two separate enzymatic activities. Different HSD17B4 variants can impair the hydratase domain, the dehydrogenase domain, or the C-terminal sterol carrier domain to different extents, resulting in three recognized subtypes of DBP deficiency (type I, II, III) with different residual activity profiles. p.Gly16Ser affects the dehydrogenase domain. In compound heterozygous individuals, the combination of Gly16Ser with a second variant in the hydratase or sterol-carrier domain may produce a more severe phenotype than two dehydrogenase-domain variants. The AGPS and AMACR genes function upstream in the peroxisomal lipid metabolism pathway; variants in these genes can produce overlapping phenotypes and should be considered in differential diagnosis when HSD17B4 testing is negative.

Your genome contains not only the code for proteins but also regulatory sequences that control how long those messages survive inside cells. The rs13900 variant in the 3' untranslated region of CCL2 — the gene encoding monocyte chemoattractant protein-1 (MCP-1) — is one of these regulatory switches. Unlike the well-studied promoter variant rs1024611 that controls how much CCL2 is made in the first place, rs13900 controls how long CCL2 mRNA survives before being degraded. A longer-lived message means more protein output even if transcription rates are identical. In individuals who carry the T allele, this post-transcriptional amplification adds meaningfully to the elevated MCP-1 levels driven by the haplotype partner rs1024611G.

The Mechanism

The rs13900 C-to-T transition in the CCL2 3' UTR alters the local RNA secondary structure in a way that enhances binding by [Human Antigen R (HuR) | HuR (ELAVL1) is a ubiquitous RNA-binding protein that stabilizes AU-rich element–containing mRNAs; it is a master regulator of inflammatory gene expression], an RNA-binding protein that stabilizes mRNAs by protecting them from nucleolytic degradation. Bioinformatic modeling predicts the T allele forms a stem-loop structure that presents a better binding surface for HuR than the C allele's predicted open conformation. Experimental validation confirmed approximately a seven-fold difference in HuR/antibody complex formation favoring the T allele (p<0.005). Nascent RNA decay experiments in heterozygous macrophage donors showed that T-allele CCL2 transcripts degrade significantly more slowly than C-allele transcripts from the same cell, with an overall CCL2 mRNA half-life of approximately 1.76 hours.

The rs13900T allele also influences mRNA [translatability | Translatability refers to how efficiently a given mRNA is loaded onto ribosomes and converted into protein, separate from transcript abundance or stability] — T-bearing transcripts showed greater association with polysomes, indicating more efficient protein synthesis per transcript molecule. The combined effect is a double amplification: more stable transcript × more efficient translation = substantially higher MCP-1 protein output per cell compared to CC homozygotes.

The Evidence

The foundational demonstration of rs13900's functional significance came from Pham et al. 2012 — 8 heterozygous donors for allelic expression imbalance (AEI) analysis¹¹ Pham et al. 2012 — 8 heterozygous donors for allelic expression imbalance (AEI) analysis
Pham MH et al. The rs1024611 regulatory region polymorphism is associated with CCL2 allelic expression imbalance. PLoS One. 2012;7(11):e49498. Using rs13900 as a transcribed proxy for the non-coding rs1024611 promoter variant, they showed that in every heterozygous individual examined, the T allele was expressed at significantly higher levels than the C allele (p=0.0009). This established that the G-T haplotype drives higher CCL2 output in vivo, not just in transfection systems.

The mechanistic detail was resolved by Akhtar et al. 2026 — 47 healthy individuals screened, 6 heterozygous donors used for stability analysis²² Akhtar et al. 2026 — 47 healthy individuals screened, 6 heterozygous donors used for stability analysis
Akhtar et al. The RNA-binding protein HuR modulates the expression of the disease-linked CCL2 rs1024611G-rs13900T haplotype. eLife. 2026, who confirmed that HuR preferentially binds T-allele transcripts in vitro (REMSA), ex vivo (RNA immunoprecipitation from primary macrophages), and that HuR overexpression selectively increases reporter activity for T-allele but not C-allele constructs (p<0.05). This places HuR as the molecular bridge between the rs13900 genotype and elevated CCL2 protein output.

The disease relevance of the CCL2-CCR2 signaling axis was directly demonstrated in a murine arteriogenesis model by Heil et al. 2004 — CCR2-knockout vs wild-type mice after femoral artery ligation³³ Heil et al. 2004 — CCR2-knockout vs wild-type mice after femoral artery ligation
Heil M et al. Collateral artery growth (arteriogenesis) after experimental arterial occlusion is impaired in mice lacking CC-chemokine receptor-2. Circ Res. 2004;94(5):671-7. CCR2-deficient mice achieved only 47% of the blood flow recovery of wild-type controls (ratio 0.21 vs 0.45) after arterial occlusion, with dramatically reduced monocyte/macrophage infiltration into perivascular collateral spaces. This establishes that high CCL2-CCR2 signaling benefits collateral vessel remodeling in ischemia — a different dimension of the same inflammatory axis that drives atherosclerosis in the non-ischemic arterial wall.

At the clinical level, Gonzalez-Quesada & Frangogiannis 2009⁴⁴ Gonzalez-Quesada & Frangogiannis 2009
Gonzalez-Quesada C, Frangogiannis NG. Monocyte chemoattractant protein-1/CCL2 as a biomarker in acute coronary syndromes. Curr Atheroscler Rep. 2009;11(2):131-8 reviewed evidence that circulating MCP-1 levels provide independent prognostic information in acute coronary syndromes — higher levels correlating with greater atherosclerotic plaque burden and worse post-infarction remodeling outcomes.

Practical Actions

The rs13900 variant has no independent clinical guidelines or ClinVar classification — its clinical relevance derives from its perfect linkage disequilibrium with the better-studied rs1024611G promoter variant. Carriers of the CT or TT genotype share the high-output CCL2 haplotype and the associated inflammatory cardiovascular risk profile. For TT homozygotes, the priority is the same set of inflammatory and lipid biomarkers that characterize rs1024611 GG carriers: hs-CRP, lipoprotein(a), and blood pressure monitoring are the most genotype-relevant tests to prioritize in cardiovascular risk assessment.

Interactions

rs13900 and rs1024611 are in perfect linkage disequilibrium (D'=1.0, r²≈1.0) in European populations and act as proxies for each other. The rs1024611G allele increases CCL2 transcription (promoter effect), while rs13900T extends mRNA half-life and improves translation efficiency (post-transcriptional effect). Together they amplify CCL2 output through two distinct mechanisms. Individuals who carry both the rs1024611 G allele and rs13900 T allele on the same haplotype — which is essentially all carriers of either, given their perfect LD — have compounded transcriptional and post-transcriptional amplification of CCL2/MCP-1.

The CCR2 receptor variant rs1799864 (V64I) modulates the downstream signaling efficiency of whatever CCL2 is produced. While this receptor variant showed no independent CAD association in the Wang 2011 meta-analysis, its interaction with the high-output CCL2 haplotype remains biologically plausible and warrants attention.

Most tremors originate in the brain or spinal cord — a glitch in neural circuitry. But heterozygous variants in MYBPC1, which encodes the slow-twitch isoform of myosin-binding protein C¹¹ myosin-binding protein C
a structural protein in the C-zone of skeletal muscle sarcomeres that regulates actomyosin cross-bridge cycling, produce a tremor that arises from the muscle itself. This condition, now formally named MYOTREM (Myopathy, Congenital, with Tremor)²² MYOTREM (Myopathy, Congenital, with Tremor)
OMIM 618524; autosomal dominant, caused by heterozygous missense mutations in MYBPC1, combines mild to moderate skeletal muscle weakness with a characteristic involuntary muscle contraction at 10–11 Hz, present from early infancy.

rs1421405659 introduces a leucine-to-proline substitution at residue 259 of the slow MyBP-C protein (p.Leu259Pro). ClinVar classifies it as Likely Pathogenic / Pathogenic across three independent submissions. A second rare allele at this same codon (T>G, p.Leu259Arg) has also been reported; both alter the same leucine residue in the conserved M-motif of the protein. The variant is absent from gnomAD population databases, consistent with strong negative selection against dominant pathogenic variants at this locus.

The Mechanism

MYBPC1 encodes slow MyBP-C, a large (~150 kDa) modular protein located at 43-nm intervals along the thick filament backbone in slow (type I) skeletal muscle fibers. Its M-motif region — the region where pathogenic variants including Leu259Pro cluster — regulates how tightly myosin heads are held in a "super-relaxed" parked state between contractions. Stavusis et al. 2019³³ Stavusis et al. 2019
Ann Neurol 86:129-142. Two MYBPC1 M-motif mutations showed approximately 3.5× increased myosin-binding affinity in biochemical assays demonstrated that pathogenic M-motif missense variants increase myosin-binding affinity by approximately 3.5-fold, preventing myosin heads from fully returning to the super-relaxed state between contractions. This persistent partial activation produces asynchronous, repetitive sarcomere contractions — the cellular basis of the 10–11 Hz myogenic tremor⁴⁴ myogenic tremor
tremor originating from within the muscle itself, not from neurological dysfunction.

Unlike cardiac MYBPC3 pathogenic variants, which disrupt myosin-head parking in the heart and cause hypertrophic cardiomyopathy, MYBPC1 Leu259Pro primarily affects slow skeletal fibers. Cardiac muscle is spared because the cardiac isoform is encoded by a different gene (MYBPC3, chr11q11).

The Evidence

Geist Hauserman et al. 2021⁵⁵ Geist Hauserman et al. 2021
JCI Insight. Characterized sarcomeric deficits in MYBPC1-associated myopathy; cohort of patients from multiple families with dominant missense variants systematically described the MYOTREM phenotype: generalized muscle weakness, hypotonia, dysmorphia, skeletal deformities (scoliosis, chest wall abnormalities, hip dysplasia), and the defining myogenic tremor. EMG studies in affected individuals show myopathic changes alongside spontaneous rhythmic discharges consistent with sarcomeric instability rather than denervation.

Lanvin et al. 2024⁶⁶ Lanvin et al. 2024
Neurol Clin Pract 14(3). Three additional pediatric patients from two families; broadened spectrum to include neonatal respiratory distress requiring noninvasive ventilation and stridor expanded the recognized phenotype to include severe neonatal respiratory compromise, highlighting that diaphragm and intercostal slow-fiber involvement can be life-threatening in the newborn period. The authors note that "tremors and respiratory distress associated with stridor should raise the diagnosis of congenital myopathy with tremors linked to MYBPC1-dominant variants in children with neonatal hypotonia."

Muscle biopsy in MYOTREM patients typically shows predominance of type I (slow) fibers with variable fiber-size disproportion, consistent with the slow-fiber-specific expression of MYBPC1. Type II fast fibers, which express MYBPC2 rather than MYBPC1, are relatively preserved.

Practical Actions

Carriers of a pathogenic MYBPC1 variant should pursue proactive neuromuscular and respiratory surveillance. The tremor is myogenic, not neurological — this means beta-blockers and other tremor medications targeting the central nervous system are unlikely to be effective, and the management focus should be on supportive myopathy care.

Respiratory involvement is the most clinically urgent concern, particularly in infancy. Annual pulmonary function testing (spirometry and forced vital capacity) is recommended once a child can cooperate, with nocturnal oximetry to screen for hypoventilation. If scoliosis develops — common in MYOTREM — spinal curvature monitoring becomes especially important as it compounds respiratory compromise.

Physiotherapy targeting slow-fiber-dominant muscles (postural muscles, hip girdle, respiratory musculature) may preserve function, but no disease-modifying pharmacotherapy currently exists. Creatine supplementation has shown modest benefit in some congenital myopathies with thin-filament involvement, though no MYBPC1-specific trials have been conducted.

Interactions

rs1421405659 (MYBPC1 Leu259Pro) is a dominant variant that acts independently — a single copy is sufficient for full clinical expression. There is no documented interaction with common modifier variants that substantially alters penetrance in published literature. However, the distal arthrogryposis phenotype (OMIM 614335) seen with MYBPC1 variants including W236R and Y856H (Gurnett et al. 2010⁷⁷ Gurnett et al. 2010
Hum Mol Genet 19(8):1462-70. First identification of MYBPC1 in DA1) may be influenced by fetal movement patterns during development, where overlapping variants affecting other sarcomeric proteins could modulate joint contracture severity.

Family screening is critical: first-degree relatives of an identified carrier have a 50% risk of inheriting the pathogenic allele. Relatives with unexplained muscle weakness, lifelong tremor, or contractures in childhood should be prioritized for genetic evaluation.

Endometriosis affects an estimated 10% of reproductive-age women and is one of the most under-diagnosed causes of chronic pelvic pain and infertility. The condition is estrogen-dependent: ectopic lesions generate their own local estrogen through elevated aromatase activity, and this autocrine loop sustains ectopic tissue proliferation and immune evasion. The GREB1 locus at chromosome 2p25.1 is among the most consistently replicated genetic risk regions in endometriosis, and rs1529868 sits within it.

GREB1 — Growth Regulation by Estrogen in Breast Cancer 1 — encodes a nuclear co-factor that physically binds steroid hormone receptors and amplifies their transcriptional output¹¹ GREB1 — Growth Regulation by Estrogen in Breast Cancer 1 — encodes a nuclear co-factor that physically binds steroid hormone receptors and amplifies their transcriptional output
Chadchan et al. Nature Communications, 2024. The gene was originally characterised in estrogen-responsive breast cancer cell lines but is expressed in endometrial tissue and plays a key role in the hormonal regulation of endometrial biology.

rs1529868 is an intronic variant at chr2:11578465 (GRCh38), positioned at c.772+34 of the primary GREB1 transcript. The GRCh38 reference allele is C; the alternate allele T is the endometriosis risk-tagged allele. Critically, rs1529868 itself has not been identified as an independent GWAS hit for endometriosis — its relevance derives from being in high linkage disequilibrium (r²=0.853 in CEU European populations) with rs11674184, the lead GWAS SNP at this locus as identified in the Rahmioglu et al. 2023 Nature Genetics multi-ancestry meta-analysis²² Rahmioglu et al. 2023 Nature Genetics multi-ancestry meta-analysis
Rahmioglu et al. The genetic basis of endometriosis and comorbidity with other pain and inflammatory conditions. Nature Genetics, 2023. At r²=0.853, rs1529868 tags approximately 85% of the variance in rs11674184 genotype status in European populations — a very high correlation that means the T allele at rs1529868 almost always co-occurs with the T risk allele at rs11674184.

The Mechanism

GREB1 operates as a context-dependent steroid hormone cofactor. In normal endometrium during the secretory phase, GREB1 supports progesterone signaling and promotes decidualization targets including WNT4 and FOXO1A³³ In normal endometrium during the secretory phase, GREB1 supports progesterone signaling and promotes decidualization targets including WNT4 and FOXO1A
Chadchan et al. 2024. In endometriotic lesions, where the cellular environment is estrogen-dominant owing to locally elevated aromatase, GREB1 switches roles — functioning as an estrogen receptor cofactor that amplifies estrogen-driven gene expression and ectopic cell proliferation. Mouse models with GREB1 knockout show substantially reduced endometriotic lesion volume and mass, and human endometriotic cells with GREB1 knockdown show reduced proliferation in response to estrogen stimulation.

GREB1 mRNA and protein are significantly elevated in peritoneal endometriotic lesions compared with eutopic endometrium from unaffected women⁴⁴ GREB1 mRNA and protein are significantly elevated in peritoneal endometriotic lesions compared with eutopic endometrium from unaffected women
Pellegrini et al. Fertility and Sterility, 2012. The rs1529868-T allele, by tagging the rs11674184-T endometriosis risk signal, is associated with this GREB1-mediated estrogen-dependent growth pathway. The precise molecular mechanism connecting intronic variation at this position to GREB1 expression or splicing has not been fully resolved; fine mapping of the GREB1 locus by Fung et al. 2015 (Human Reproduction)⁵⁵ Fung et al. 2015 (Human Reproduction)
Fung et al. Fine mapping of GREB1 in endometriosis, 2015 identified multiple intronic variants with independent association signals, suggesting a complex regulatory landscape containing several functional elements.

The Evidence

The GREB1 locus was first established for endometriosis in a multi-population meta-analysis of 4,604 cases and 9,393 controls⁶⁶ multi-population meta-analysis of 4,604 cases and 9,393 controls
Nyholt et al. Nature Genetics, 2012 using rs13394619 as the index SNP (OR=1.15, P=6.1×10⁻⁸). The landmark Rahmioglu et al. 2023 Nature Genetics GWAS⁷⁷ Rahmioglu et al. 2023 Nature Genetics GWAS
Rahmioglu et al. 2023 — the largest endometriosis genetic study to date, incorporating data from 23andMe and major international biobanks — identified rs11674184, the variant in high LD with rs1529868, as a statistically independent and more significant signal at the same GREB1 locus: OR=1.13 (95% CI 1.10–1.15, P=3×10⁻¹⁷) for all endometriosis, strengthening to OR=1.16 (P=6×10⁻⁹) specifically for Stage III/IV moderate-to-severe disease.

Because rs1529868 itself is not independently catalogued in the GWAS Catalog and has no direct ClinVar entry, its evidence rating is appropriately moderate — the underlying biology and locus-level evidence are strong (established in multiple large GWAS), but the specific genetic contribution of rs1529868 is inferred through its LD relationship with rs11674184 rather than through direct association testing. At r²=0.853, this inference is highly reliable in European populations; it may be less reliable in populations where LD structure differs.

The T allele frequency shows modest ancestry stratification: approximately 0.55 in European and East Asian populations, approximately 0.47 in African populations, and approximately 0.60 in South Asian populations. The somewhat higher African C allele frequency (~0.53) means that, in women of African ancestry, TT genotypes are less common (~22%) compared to European women (~30%).

Practical Implications

For women carrying the T allele at rs1529868, the clinical guidance mirrors that for rs11674184-T carriers, given the high LD. The key actionable implication is prompt recognition of endometriosis symptoms rather than normalizing them. Endometriosis diagnostic delay averages 7–9 years across many healthcare systems, driven by normalization of menstrual pain and the requirement for laparoscopic confirmation. Women carrying one or two T alleles have elevated probability of endometriosis — and specifically moderate-to-severe Stage III/IV disease — and carry the strongest genetic motivation to pursue early specialist evaluation rather than waiting for symptoms to escalate.

Interactions

rs11674184 (GREB1): The lead GWAS SNP for the endometriosis signal at this locus (OR=1.13, P=3×10⁻¹⁷ in Rahmioglu 2023), in high LD with rs1529868 (r²=0.853 CEU). Most women with TT at rs1529868 will also carry TT at rs11674184. The two variants largely capture the same biological signal and should not be treated as fully independent additive risk factors.

rs13394619 (GREB1): A second intronic GREB1 variant at 2p25.1 (r²=0.65 with rs11674184 in Europeans, and therefore in moderate but imperfect LD with rs1529868). The three GREB1 variants — rs1529868, rs11674184, and rs13394619 — represent overlapping but distinct aspects of the GREB1 regulatory landscape. For supervisor compound action proposal: women carrying the T risk allele at rs1529868 (TT or CT) AND the G risk allele at rs13394619 (GG or AG) carry two partially independent GREB1 risk signals. Combined recommendation: lower threshold for specialist gynecological referral, earlier baseline ovarian reserve testing (AMH + antral follicle count), and proactive fertility counseling. Evidence level: moderate.

rs12700667 (7p15.2, HOXA locus): The other major replicated endometriosis GWAS locus, operating through distinct long-range regulation of HOXA10/HOXA11 — independent of the GREB1 pathway. Both loci show additive effects on endometriosis risk and both show enriched effects at Stage III/IV. Women carrying T alleles at rs1529868 AND risk alleles at rs12700667 carry the two strongest common endometriosis genetic signals simultaneously.